A whole set of beliefs has formed around testosterone isocaproate over the years of the existence of sports forums, which pass from one author to another without verification. The editors have collected the most common of them and compared them with what is known from the pharmacology and clinical studies of testosterone.
Where do myths about esters come from?
Most of the myths about isocaproate arise from one basic misunderstanding: the ester is perceived as a separate substance with its own "properties". Testosterone isocaproate is actually a prodrug. After isocaproic acid is split off, normal testosterone, identical to that produced by the testicles, circulates in the blood.
The second source of myths is that isocaproate almost does not exist in medical practice as an independent remedy. It is known mainly as a component of Sustanon 250-type mixtures. When there is little clinical data on a single ester, the space is filled with personal impressions that cannot be separated from the placebo effect, training and nutrition.
The third source is the marketing of the illegal market. It is profitable for sellers to present different esters as products with unique characteristics: "dry", "soft", "clean". None of these terms has a pharmacological meaning.
Finally, confirmation bias plays a role. A person who expects a certain effect tends to notice it. This is why medicine relies on randomized controlled trials rather than subjective reports.
Myths about "softness" and power of action
Myth 1: "Isocaproate is a soft ester, so it's safer." Ester determines only the rate of release of the hormone from the oil depot. The profile of side effects is determined by the total amount of testosterone and the duration of exposure. Bhasin et al.'s (2001) study with enanthate showed that both anabolic effects and HDL-lowering increased in proportion to testosterone dose—not dependent on ester name.
Myth 2: "Isocaproate is stronger than enanthate." In fact, per milligram of ester, isocaproate contains slightly more pure testosterone (about 75% by weight vs. about 72% in enanthate) because of the shorter chain. The difference is small and does not make the drug "stronger" in a qualitative sense.
Myth 3: "The mixture with isocaproate gives a perfectly even level of the hormone." The idea of the mixtures was indeed to smooth out the curve, but in reality there is a noticeable peak after the injection followed by a gradual decrease. The mixture does not eliminate the oscillations, but only changes their form.
Myth 4: "Isocaproate causes less water retention than enanthate." Fluid retention is related to estradiol levels, sodium in the diet, and total androgen dose. Ester does not affect this: after cleavage, the molecule is the same.
Myths about hormones and estrogens
Myth 5: "Isocaproate does not suppress your own testosterone." This is one of the most dangerous mistakes. Any exogenous testosterone suppresses the secretion of LH and FSH through a negative feedback loop. WHO studies on hormonal contraception have shown that testosterone in medical doses can cause azoospermia in a large part of healthy men.
Myth 6: "Short and medium esters do not aromatize." Aromatase acts on the testosterone molecule, not the ester. After splitting off isocaproic acid, the hormone is converted to estradiol in the same way as any other testosterone. The degree of aromatization depends on the hormone level, the amount of adipose tissue and individual characteristics.
Myth 7: "If the ester is removed faster, the axis will recover faster." Recovery is determined not only by when the drug leaves the body, but also by how long and deeply the axis was suppressed. Kanayama et al (2015) described cases of prolonged hypogonadism after withdrawal of anabolic steroids that do not fit the notion of “rapid recovery”.
Myth 8: "Estrogen should always be suppressed." In men, estradiol is needed for bone density, lipid metabolism and libido. Unreasonable use of drugs to reduce it has its own risks. The decision on correction is made by the doctor in the presence of symptoms and tests.
| Myth | What does science say? |
|---|---|
| Isocaproate is "softer" and safer | The risks depend on the testosterone dose and duration, not the ester |
| Does not suppress the GGTO axis | Any exogenous testosterone suppresses LH and FSH |
| Not flavored | After cleavage of the ester, testosterone aromatizes as usual |
| The mixture gives an even background | After the injection there is a peak and a gradual decrease |
| Small doses are safe for women | Even small doses raise testosterone to male levels |
| Not detected by doping control | Testosterone and its esters are prohibited by WADA and detected |
Myths about security, women and control
Myth 9: "If nothing hurts, everything is fine." The most serious effects of testosterone — an increase in hematocrit, a decrease in HDL, an increase in blood pressure — have no symptoms for a long time. Coviello et al. (2008) demonstrated a dose-dependent increase in hematocrit that is not experienced by the individual. Only analyzes allow us to see these changes.
Myth 10: "Women are safe in small doses." The normal level of testosterone in women is about 15 times lower than in men. Therefore, even a small volume of injected ester raises it to supraphysiological values. The hoarseness of the voice and the enlargement of the clitoris may be irreversible.
Myth 11: "Doping control does not distinguish injectable testosterone from its own." Testosterone and its esters are included in Section S1 of the WADA Prohibited List. Anti-doping laboratories use a complex of methods, including analysis of the steroid profile within the athlete's biological passport and isotope mass spectrometry. The editors do not discuss any ways of evading control: the use of prohibited substances in sports is a violation of anti-doping rules.
Myth 12: "A drug from the Internet is the same as a drug from a pharmacy." On the uncontrolled market there are products with the wrong concentration, a different composition of esters or broken sterility. An injection of a non-sterile solution can lead to an abscess, and a dose mismatch can lead to unpredictable effects.
- Ester is only "packaging", testosterone works.
- Risks are determined by dose and duration.
- The absence of symptoms does not mean the absence of changes in the tests.
- For women, some of the consequences are irreversible.
How to check information
The first rule is to distinguish between sources. Clinical guidelines, systematic reviews, and randomized trials have a higher evidentiary value than individual clinical cases, and those, in turn, are more reliable than anonymous feedback on forums.
The second rule is to find out what situation the data belongs to. Results obtained at medical doses in patients with hypogonadism are not transferred to supraphysiological doses in healthy individuals, and vice versa.
The third rule is to beware of categorical statements such as "completely without side effects" or "completely safe". There are no such substances in pharmacology: any active drug has a benefit-risk ratio.
The fourth rule is to pay attention to the motivation of the author. A source selling a product or profiting from its popularity will rarely be unbiased.
Editorial conclusion
Most of the myths about testosterone isocaproate are based on the idea that the ester gives the hormone special properties. In fact, all of its effects are those of testosterone, and the ester only changes the rate of release.
The most dangerous myths are those that downplay the risks: about the lack of axis suppression, safety for women, and the "invisibility" of changes. They can lead to infertility, irreversible virilization or cardiovascular problems.
A critical attitude to sources and regular medical control is the best protection against misinformation.
We recommend that you also read our articles on the history of the creation of testosterone isocaproate, on the tests to control its use and on the effect on your own testosterone production.
References
- Bhasin S, Woodhouse L, Casaburi R, et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab. 2001;281(6):E1172âE1181.
- Coviello AD, Kaplan B, Lakshman KM, et al. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. J Clin Endocrinol Metab. 2008;93(3):914â919.
- World Health Organization Task Force on Methods for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet. 1990;336(8721):955â959.
- Kanayama G, Hudson JI, DeLuca J, et al. Prolonged hypogonadism in males following withdrawal from anabolic-androgenic steroids: an under-recognized problem. Addiction. 2015;110(5):823â831.
- Handelsman DJ, Hirschberg AL, Bermon S. Circulating testosterone as the hormonal basis of sex differences in athletic performance. Endocr Rev. 2018;39(5):803â829.
- Pope HG Jr, Wood RI, Rogol A, et al. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocr Rev. 2014;35(3):341â375.
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List. Montreal: WADA; 2025.
